Saturday, July 02, 2022 3:03:01 PM
I'm not surprised there was very little change in Lp-PLA2 in R-IT in the V group - but a level of 134 is almost normal - sorta throws shade on my long held belief that Lp-PLA2 is a significant risk marker for CVD - perhaps it's just a marker for stroke risk? Most of these patients should have had inflamed arteries - that's part of heart disease - very odd that levels were so low at baseline - but the MO group's levels went up by 25% during the course of the trial - to me that shows disease progression, but still doesn't explain why levels were so low to start with. I would love to see a breakout of data between patients with established CVD and those who were in the trial for primary prevention (risk factors but no CVD) - wonder if the latter group, being healthier, artificially lowered the baseline number.
Interleukin-6 and hs-CRP are or can be transient responses to acute trauma or infection - 5 years ago when a tooth with an old root canal got infected, forming a massive abscess, that required pulling the tooth and installing an implant***, my hs-CRP soared from 2 to 9. I'm not concerned with those results, too many things can make them go up or down. Results for homocysteine were unremarkable for both groups, very little change - but as I wrote, I would not expect EPA to affect levels - homocysteine is almost totally controlled by the intake and absorption of several crucial B vitamins, and the body's ability to use those B's is directly related to the MTHFR gene, and I have a defective allele on that gene (it's only half functional). I take methylated forms of 3 B vitamins (6, 9, 12), but it's hard to impossible to take enough B-12 to overcome the MTHFR defect - the amount contained in DS is extremely tiny, as in 3 to 5 micrograms (6 and 9 are mg's). Several years ago I tried doubling my B-12 doses but it caused intense itching of the skin of my back - the keep you awake at night kind of insane itching, and it was not dry skin - I tried applying moisturizing creams plus almond oil several times per day - nothing worked - but the itching went away when I went back to my prior dosages. There's a medical cause for that B-12 itching but I forget what it is.
**** I saw a holistic dentist to treat that abscess - we attempted to keep the tooth with injections of ozonated water and antibiotics, but they only reduced the abscess size a little bit, tooth had to come out - that infection could have gone into my brain or heart because it had direct access to my bloodstream. When he pulled the tooth the stench was unbelievable, almost made me retch - he said there was a mass of infected tissue the size of a small gumball attached to the roots. When he walked out of the room into the hallway with his assistant to dispose of it he whispered to her "that's why we don't do root canals" - it's hard to remove all of the live tissue, and if any remains it can get infected if the root sealant leaks. In this case I had been using a wrench to try to remove a stubborn bolt from something in my shop, and when it suddenly broke free my hand snapped straight back into my mouth, smacking the gums above that front tooth with the end of the wrench - ouch! Ended up costing me $5k - implants are EXPENSIVE!!
The Thought Police: To censor and protect. Craig Bruce
Recent AMRN News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM